Experimental group:Romiplostim N01

4 trials

Sponsors

Tianjin Medical University General Hospital, Anhui provincial hospital (The First Affiliated Hospital of University of Science and Technology of China), Yantai Yuhuangding Hospital, Zhongshan Hospital Affiliated to Xiamen University

Conditions

Chemotherapy-Induced ThrombocytopeniaGynecological CancerOxaliplatin-containing chemotherapy–induced thrombocytopeniaSepsis was associated with thrombocytopenia

Phase 2

A prospective, multicenter, exploratory study of loplastine N01 in the treatment of thrombocytopenia caused by chemotherapy containing paclitaxel in breast cancer or gynecological tumors

RecruitingChiCTR2500106713

Anhui provincial hospital (The First Affiliated Hospital of University of Science and Technology of China)Chemotherapy-Induced Thrombocytopenia

Start: 2025-07-29Updated: 2025-08-18

Efficacy and Safety of XL-CTIT-PP Model–Guided Primary Prophylaxis With Romiplostim N01 for Oxaliplatin-Containing Chemotherapy–Induced Thrombocytopenia: A Clinical Study

Active, not recruitingChiCTR2600131326

Zhongshan Hospital Affiliated to Xiamen UniversityOxaliplatin-containing chemotherapy–induced thrombocytopenia

Start: 2026-09-01Updated: 2026-09-07

Phase 4

Exploring the Efficacy and Safety of Romiplostim N01 in Chemotherapy-Induced Thrombocytopenia Among Gynecological Cancer Patients: A Prospective Clinical Study

Active, not recruitingChiCTR2500102416

Tianjin Medical University General HospitalGynecological Cancer

Start: 2025-06-01Updated: 2025-05-19

Unknown Phase

Romiplostim N01 for Sepsis-associated Thrombocytopenia: A Single-center, Single-arm Clinical Study

Active, not recruitingChiCTR2600124669

Yantai Yuhuangding HospitalSepsis was associated with thrombocytopenia

Start: 2026-05-15Updated: 2026-05-18